BioPharma Credit (BOPC.F) 주식 개요투자 신탁인 BioPharma Credit PLC는 주로 이자부채 자산에 투자합니다. 자세히 보기BOPC.F 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적4/6재무 건전성6/6배당3/6강점공정 가치 추정치보다 낮은 30.6% 에서 거래지난 5년 동안 수입이 매년 5.2% 증가했습니다.위험 분석주식은 유동성이 매우 낮습니다10.28% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.모든 위험 점검 보기BOPC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.9611.3% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0218m2016201920222025202620282031Revenue US$208.4mEarnings US$171.6mAdvancedSet Fair ValueView all narrativesBioPharma Credit PLC 경쟁사Virtus Investment PartnersSymbol: NYSE:VRTSMarket cap: US$1.1bAdams Natural Resources FundSymbol: NYSE:PEOMarket cap: US$750.8mNoah HoldingsSymbol: NYSE:NOAHMarket cap: US$577.1mRidgepost CapitalSymbol: NYSE:RPCMarket cap: US$909.8m가격 이력 및 성과BioPharma Credit 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.9652주 최고가US$1.0252주 최저가US$0.85베타0.181개월 변동-2.29%3개월 변동0.80%1년 변동12.66%3년 변동10.07%5년 변동1.87%IPO 이후 변동-15.26%최근 뉴스 및 업데이트공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend for Quarter Ending 30 June 2026, Payable on 31 July 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026. The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).공고 • May 06BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026. Location: the offices of herbert smith freehills llp, exchange house, primrose street, ec2a 2eg, london United Kingdom공고 • Apr 24BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 31 March 2026, Payable on 29 May 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 31 March 2026 of 1.75 cents per share, payable on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026. The ex-dividend date will be 30 April 2026. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these have been supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).공고 • Feb 11+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 20 March 2026BioPharma Credit PLC declared an special dividend in respect of the quarterly financial period ending 31 December 2025. For the period company declared special dividend of 1.446044 cents per share, payable on 20 March 2026 to ordinary shareholders on the register as at 20 February 2026. The ex-dividend date will be 19 February 2026.공고 • Feb 03BioPharma Credit PLC to Report Fiscal Year 2025 Results on Mar 24, 2026BioPharma Credit PLC announced that they will report fiscal year 2025 results on Mar 24, 2026공고 • Aug 26BioPharma Credit PLC to Report Q2, 2025 Results on Sep 22, 2025BioPharma Credit PLC announced that they will report Q2, 2025 results on Sep 22, 2025더 많은 업데이트 보기Recent updates공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend for Quarter Ending 30 June 2026, Payable on 31 July 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026. The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).공고 • May 06BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026. Location: the offices of herbert smith freehills llp, exchange house, primrose street, ec2a 2eg, london United Kingdom공고 • Apr 24BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 31 March 2026, Payable on 29 May 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 31 March 2026 of 1.75 cents per share, payable on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026. The ex-dividend date will be 30 April 2026. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these have been supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).공고 • Feb 11+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 20 March 2026BioPharma Credit PLC declared an special dividend in respect of the quarterly financial period ending 31 December 2025. For the period company declared special dividend of 1.446044 cents per share, payable on 20 March 2026 to ordinary shareholders on the register as at 20 February 2026. The ex-dividend date will be 19 February 2026.공고 • Feb 03BioPharma Credit PLC to Report Fiscal Year 2025 Results on Mar 24, 2026BioPharma Credit PLC announced that they will report fiscal year 2025 results on Mar 24, 2026공고 • Aug 26BioPharma Credit PLC to Report Q2, 2025 Results on Sep 22, 2025BioPharma Credit PLC announced that they will report Q2, 2025 results on Sep 22, 2025공고 • Aug 21BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 169,286,233 shares, representing 14.99% of its issued share capital, under the authorization approved on June 9, 2025.BioPharma Credit PLC (LSE:BPCR) commences share repurchases on August 20, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 9, 2025. As per the mandate, the company is authorized to repurchase up to 169,286,233 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2026. As of May 6, 2025, the company had 1,373,932,067 shares in issue of which 244,604,289 shares were in treasury.공고 • Jul 31BioPharma Credit PLC Appoints Nigel Reynolds as Non-Executive Director, Effective 1 January 2026BioPharma Credit PLC announced the appointment of Nigel Reynolds as a non-executive Director with effect from 1 January 2026, following his retirement from PwC on 31 December 2025. Mr. Reynolds will, after a transition period, take over as chair of the Company's Audit and Risk committee. Mr. Reynolds has 34 years of accounting and finance experience advising both listed and private companies. He has been a partner at PwC for 20 years specialising in audit, transaction services and capital markets work. During his time at PwC, he led its London Assurance practice for 5 years, led the private equity portfolio company practice and was the relationship partner for various UK listed and international companies including companies in healthcare and investment trusts. Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability, and other large projects for PwC clients.공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 30 June 2025, Payable on 31 July 2025BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2025 of 1.75 cents per share, payable on 31 July 2025 to ordinary shareholders on the register as at 27 June 2025. The ex-dividend date will be 26 June 2025.공고 • Mar 26+ 1 more updateBioPharma Credit PLC, Annual General Meeting, Jun 09, 2025BioPharma Credit PLC, Annual General Meeting, Jun 09, 2025.공고 • Feb 20BioPharma Credit PLC to Report Fiscal Year 2024 Results on Mar 25, 2025BioPharma Credit PLC announced that they will report fiscal year 2024 results on Mar 25, 2025공고 • Jan 23+ 1 more updateBioPharma Credit PLC Declares Special Dividend, Payable on February 28, 2025BioPharma Credit PLC declares special dividend of 1.142309 cents. The ex-dividend date will be 30 January 2025, payable on 28 February 2025 to ordinary shareholders on the register as at 31 January 2025.공고 • Sep 19+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 29 October 2024BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 September 2024 of 3.75 cents per share. BPCR will also be declaring an interim dividend for the calendar year ending 31 December 2023 of 0.039155 cents per ordinary share to distribute the remaining revenue reserves for the calendar year 2023. Both interim dividends will be payable on 29 October 2024 to ordinary shareholders on the register as at 27 September 2024. The 3.789155 cents dividend comprises an ordinary dividend of 1.75 cents and a special dividend of 2.039155 cents. The ex-dividend date will be 26 September 2024.공고 • Aug 16BioPharma Credit PLC to Report First Half, 2024 Results on Sep 24, 2024BioPharma Credit PLC announced that they will report first half, 2024 results on Sep 24, 2024공고 • Jul 31BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 185,505,277 shares, representing 14.99% of its issued share capital, under the authorization approved on June 12, 2024.BioPharma Credit PLC (LSE:BPCR) commences share repurchases on July 30, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 12, 2024. As per the mandate, the company is authorized to repurchase up to 185,505,277 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2025. As of April 15, 2024, the company had 1,237,526,871 shares in issue of which 136,405,196 shares were in treasury.공고 • Jun 22BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2024, Payable on 31 July 2024BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2024 of $0.0175 per ordinary share, payable on 31 July 2024 to ordinary shareholders on the register as at 5 July 2024. The ex-dividend date will be 4 July 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7-cent annual dividend per ordinary share.공고 • Mar 27BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024.공고 • Mar 22Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 31 March 2024 of $0.0175 per ordinary share, payable on 30 April 2024 to ordinary shareholders on the register as at 2 April 2024. The ex-dividend date will be 28 March 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.공고 • Feb 27BioPharma Credit PLC to Report Fiscal Year 2023 Results on Mar 27, 2024BioPharma Credit PLC announced that they will report fiscal year 2023 results on Mar 27, 2024공고 • Feb 08+ 1 more updateBioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024BioPharma Credit PLC declared an interim special dividend in respect of the financial period ending 31 December 2023 of $0.01207930 per ordinary share, payable on 15 March 2024 to ordinary shareholders on the register as at 16 February 2024. The ex-dividend date will be 15 February 2024.공고 • Nov 29+ 1 more updateBiopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024BioPharma Credit PLC declare an interim dividend in respect of the financial period ended 30 September 2023 of $0.0375 per ordinary share, payable on 5 January 2024 to ordinary shareholders on the register as at 8 December 2023. The ex-dividend date will be 7 December 2023. The $0.0375 dividend comprises an ordinary dividend of $0.0175 and a special dividend of $0.0200The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.공고 • Sep 27BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023BioPharma Credit PLC provided dividend guidance for the full year ending December 31, 2023. For the period, the company's target dividend of 7 cents per annum (December 31, 2022: 7 cents per annum).공고 • Aug 31BioPharma Credit PLC to Report Q2, 2023 Results on Sep 27, 2023BioPharma Credit PLC announced that they will report Q2, 2023 results on Sep 27, 2023공고 • Aug 11BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2023, Payable on 15 September 2023BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2023 of $0.0175 per ordinary share, payable on 15 September 2023 to ordinary shareholders on the register as at 18 August 2023. The ex-dividend date will be 17 August 2023.주주 수익률BOPC.FUS Capital MarketsUS 시장7D0%-3.0%-1.4%1Y12.7%1.2%16.4%전체 주주 수익률 보기수익률 대 산업: BOPC.F은 지난 1년 동안 1.2%의 수익을 기록한 US Capital Markets 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: BOPC.F은 지난 1년 동안 16.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is BOPC.F's price volatile compared to industry and market?BOPC.F volatilityBOPC.F Average Weekly Movementn/aCapital Markets Industry Average Movement3.8%Market Average Movement7.1%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.2%안정적인 주가: BOPC.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine BOPC.F의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2016n/an/awww.bpcruk.com투자 신탁인 BioPharma Credit PLC는 주로 이자부채 자산에 투자합니다. 회사 부채 자산은 승인된 생명과학 제품의 판매에서 발생하는 로열티 또는 기타 현금 흐름으로 담보됩니다. 2016년에 설립되었으며 영국 리즈에 본사를 두고 있습니다.더 보기BioPharma Credit PLC 기초 지표 요약BioPharma Credit의 순이익과 매출은 시가총액과 어떻게 비교됩니까?BOPC.F 기초 통계시가총액US$1.09b순이익 (TTM)US$129.89m매출 (TTM)US$157.75m8.4x주가수익비율(P/E)6.9x주가매출비율(P/S)BOPC.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표BOPC.F 손익계산서 (TTM)매출US$157.75m매출원가US$0총이익US$157.75m기타 비용US$27.86m순이익US$129.89m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)0.12총이익률100.00%순이익률82.34%부채/자본 비율0%BOPC.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당10.3%현재 배당 수익률61%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 23:49종가2026/06/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioPharma Credit PLC는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matthew HoseJefferies LLC
공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend for Quarter Ending 30 June 2026, Payable on 31 July 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026. The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).
공고 • May 06BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026. Location: the offices of herbert smith freehills llp, exchange house, primrose street, ec2a 2eg, london United Kingdom
공고 • Apr 24BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 31 March 2026, Payable on 29 May 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 31 March 2026 of 1.75 cents per share, payable on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026. The ex-dividend date will be 30 April 2026. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these have been supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).
공고 • Feb 11+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 20 March 2026BioPharma Credit PLC declared an special dividend in respect of the quarterly financial period ending 31 December 2025. For the period company declared special dividend of 1.446044 cents per share, payable on 20 March 2026 to ordinary shareholders on the register as at 20 February 2026. The ex-dividend date will be 19 February 2026.
공고 • Feb 03BioPharma Credit PLC to Report Fiscal Year 2025 Results on Mar 24, 2026BioPharma Credit PLC announced that they will report fiscal year 2025 results on Mar 24, 2026
공고 • Aug 26BioPharma Credit PLC to Report Q2, 2025 Results on Sep 22, 2025BioPharma Credit PLC announced that they will report Q2, 2025 results on Sep 22, 2025
공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend for Quarter Ending 30 June 2026, Payable on 31 July 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2026 of 1.75 cents per share, payable on 31 July 2026 to ordinary shareholders on the register as at 3 July 2026. The ex-dividend date will be 2 July 2026. The Company aims to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these are supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).
공고 • May 06BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026BioPharma Credit PLC, Annual General Meeting, Jun 17, 2026. Location: the offices of herbert smith freehills llp, exchange house, primrose street, ec2a 2eg, london United Kingdom
공고 • Apr 24BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 31 March 2026, Payable on 29 May 2026BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 31 March 2026 of 1.75 cents per share, payable on 29 May 2026 to ordinary shareholders on the register as at 1 May 2026. The ex-dividend date will be 30 April 2026. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from its investments in the life sciences industry. The Company currently pays, and continues to target, a 7-cent base annual dividend per ordinary share in four quarterly payments of 1.75 cents per share. Typically, these have been supplemented by excess income in the form of special dividend distributions in Fourth Quarter and in some years, Third Quarter and Q4, where the Board determines that it is appropriate and able to do so (noting the requirement to pay out substantially all income to maintain the Company's investment trust status).
공고 • Feb 11+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 20 March 2026BioPharma Credit PLC declared an special dividend in respect of the quarterly financial period ending 31 December 2025. For the period company declared special dividend of 1.446044 cents per share, payable on 20 March 2026 to ordinary shareholders on the register as at 20 February 2026. The ex-dividend date will be 19 February 2026.
공고 • Feb 03BioPharma Credit PLC to Report Fiscal Year 2025 Results on Mar 24, 2026BioPharma Credit PLC announced that they will report fiscal year 2025 results on Mar 24, 2026
공고 • Aug 26BioPharma Credit PLC to Report Q2, 2025 Results on Sep 22, 2025BioPharma Credit PLC announced that they will report Q2, 2025 results on Sep 22, 2025
공고 • Aug 21BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 169,286,233 shares, representing 14.99% of its issued share capital, under the authorization approved on June 9, 2025.BioPharma Credit PLC (LSE:BPCR) commences share repurchases on August 20, 2025, under the program mandated by the shareholders in the Annual General Meeting held on June 9, 2025. As per the mandate, the company is authorized to repurchase up to 169,286,233 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2026. As of May 6, 2025, the company had 1,373,932,067 shares in issue of which 244,604,289 shares were in treasury.
공고 • Jul 31BioPharma Credit PLC Appoints Nigel Reynolds as Non-Executive Director, Effective 1 January 2026BioPharma Credit PLC announced the appointment of Nigel Reynolds as a non-executive Director with effect from 1 January 2026, following his retirement from PwC on 31 December 2025. Mr. Reynolds will, after a transition period, take over as chair of the Company's Audit and Risk committee. Mr. Reynolds has 34 years of accounting and finance experience advising both listed and private companies. He has been a partner at PwC for 20 years specialising in audit, transaction services and capital markets work. During his time at PwC, he led its London Assurance practice for 5 years, led the private equity portfolio company practice and was the relationship partner for various UK listed and international companies including companies in healthcare and investment trusts. Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability, and other large projects for PwC clients.
공고 • Jun 19BioPharma Credit PLC Declares Interim Dividend in Respect of the Quarterly Financial Period Ending 30 June 2025, Payable on 31 July 2025BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 June 2025 of 1.75 cents per share, payable on 31 July 2025 to ordinary shareholders on the register as at 27 June 2025. The ex-dividend date will be 26 June 2025.
공고 • Mar 26+ 1 more updateBioPharma Credit PLC, Annual General Meeting, Jun 09, 2025BioPharma Credit PLC, Annual General Meeting, Jun 09, 2025.
공고 • Feb 20BioPharma Credit PLC to Report Fiscal Year 2024 Results on Mar 25, 2025BioPharma Credit PLC announced that they will report fiscal year 2024 results on Mar 25, 2025
공고 • Jan 23+ 1 more updateBioPharma Credit PLC Declares Special Dividend, Payable on February 28, 2025BioPharma Credit PLC declares special dividend of 1.142309 cents. The ex-dividend date will be 30 January 2025, payable on 28 February 2025 to ordinary shareholders on the register as at 31 January 2025.
공고 • Sep 19+ 1 more updateBiopharma Credit plc Declares Special Dividend, Payable on 29 October 2024BioPharma Credit PLC declared an interim dividend in respect of the quarterly financial period ending 30 September 2024 of 3.75 cents per share. BPCR will also be declaring an interim dividend for the calendar year ending 31 December 2023 of 0.039155 cents per ordinary share to distribute the remaining revenue reserves for the calendar year 2023. Both interim dividends will be payable on 29 October 2024 to ordinary shareholders on the register as at 27 September 2024. The 3.789155 cents dividend comprises an ordinary dividend of 1.75 cents and a special dividend of 2.039155 cents. The ex-dividend date will be 26 September 2024.
공고 • Aug 16BioPharma Credit PLC to Report First Half, 2024 Results on Sep 24, 2024BioPharma Credit PLC announced that they will report first half, 2024 results on Sep 24, 2024
공고 • Jul 31BioPharma Credit PLC (LSE:BPCR) commences an Equity Buyback Plan for 185,505,277 shares, representing 14.99% of its issued share capital, under the authorization approved on June 12, 2024.BioPharma Credit PLC (LSE:BPCR) commences share repurchases on July 30, 2024, under the program mandated by the shareholders in the Annual General Meeting held on June 12, 2024. As per the mandate, the company is authorized to repurchase up to 185,505,277 shares, representing 14.99% of issued share capital. The minimum price which may be paid per any ordinary share is US$0.01 and The maximum price which may be paid for any ordinary share is the higher of 5% above the average of the mid-market values of such ordinary share for the five business days before the purchase is made, or the higher of the price of the last independent trade and the highest current independent bid for such ordinary share. The shares repurchased pursuant to the buyback will be cancelled or held in treasury. The repurchase program is valid till next Annual General Meeting to be held in 2025. As of April 15, 2024, the company had 1,237,526,871 shares in issue of which 136,405,196 shares were in treasury.
공고 • Jun 22BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2024, Payable on 31 July 2024BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2024 of $0.0175 per ordinary share, payable on 31 July 2024 to ordinary shareholders on the register as at 5 July 2024. The ex-dividend date will be 4 July 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7-cent annual dividend per ordinary share.
공고 • Mar 27BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024BioPharma Credit PLC, Annual General Meeting, Jun 12, 2024.
공고 • Mar 22Biopharma Credit plc Declares Interim Dividend in Respect of the Financial Period Ending 31 March 2024, Payable on 30 April 2024BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 31 March 2024 of $0.0175 per ordinary share, payable on 30 April 2024 to ordinary shareholders on the register as at 2 April 2024. The ex-dividend date will be 28 March 2024. The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.
공고 • Feb 27BioPharma Credit PLC to Report Fiscal Year 2023 Results on Mar 27, 2024BioPharma Credit PLC announced that they will report fiscal year 2023 results on Mar 27, 2024
공고 • Feb 08+ 1 more updateBioPharma Credit PLC Declares Interim Special Dividend in Respect of the Financial Period Ending 31 December 2023, Payable on 15 March 2024BioPharma Credit PLC declared an interim special dividend in respect of the financial period ending 31 December 2023 of $0.01207930 per ordinary share, payable on 15 March 2024 to ordinary shareholders on the register as at 16 February 2024. The ex-dividend date will be 15 February 2024.
공고 • Nov 29+ 1 more updateBiopharma Credit plc Declares Special Dividend in Respect of the Financial Period Ended 30 September 2023, Payable on 5 January 2024BioPharma Credit PLC declare an interim dividend in respect of the financial period ended 30 September 2023 of $0.0375 per ordinary share, payable on 5 January 2024 to ordinary shareholders on the register as at 8 December 2023. The ex-dividend date will be 7 December 2023. The $0.0375 dividend comprises an ordinary dividend of $0.0175 and a special dividend of $0.0200The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
공고 • Sep 27BioPharma Credit PLC Provides Dividend Guidance for the Full Year Ending December 31, 2023BioPharma Credit PLC provided dividend guidance for the full year ending December 31, 2023. For the period, the company's target dividend of 7 cents per annum (December 31, 2022: 7 cents per annum).
공고 • Aug 31BioPharma Credit PLC to Report Q2, 2023 Results on Sep 27, 2023BioPharma Credit PLC announced that they will report Q2, 2023 results on Sep 27, 2023
공고 • Aug 11BioPharma Credit PLC Declares Interim Dividend in Respect of the Financial Period Ending 30 June 2023, Payable on 15 September 2023BioPharma Credit PLC declared an interim dividend in respect of the financial period ending 30 June 2023 of $0.0175 per ordinary share, payable on 15 September 2023 to ordinary shareholders on the register as at 18 August 2023. The ex-dividend date will be 17 August 2023.
